$28.8
+0.19
(+0.66%)▲
Insights on Immunovant Inc
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 154.2%
1.04%
Downside
Day's Volatility :3.52%
Upside
2.51%
44.79%
Downside
52 Weeks Volatility :65.12%
Upside
36.81%
Period | Immunovant Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.69% | 1.7% | 0.0% |
6 Months | -15.18% | 11.3% | 0.0% |
1 Year | 78.11% | 5.4% | 1.3% |
3 Years | 80.79% | 13.9% | -22.1% |
Market Capitalization | 4.2B |
Book Value | $4.68 |
Earnings Per Share (EPS) | -1.81 |
Wall Street Target Price | 50.86 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -27.15% |
Return On Equity TTM | -44.51% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -253.4M |
Diluted Eps TTM | -1.81 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.77 |
EPS Estimate Next Year | -1.86 |
EPS Estimate Current Quarter | -0.43 |
EPS Estimate Next Quarter | -0.45 |
What analysts predicted
Upside of 76.6%
Sell
Neutral
Buy
Immunovant Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Immunovant Inc | -7.75% | -15.18% | 78.11% | 80.79% | 189.45% |
Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Immunovant Inc | NA | NA | NA | -1.77 | -0.45 | -0.27 | NA | 4.68 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Immunovant Inc | Buy | $4.2B | 189.45% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
FMR Inc
Vanguard Group Inc
BlackRock Inc
State Street Corporation
Perceptive Advisors LLC
T. Rowe Price Associates, Inc.
Immunovant Inc’s price-to-earnings ratio stands at None
Read Moreimmunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
Organization | Immunovant Inc |
Employees | 164 |
CEO | Dr. Frank M. Torti M.B.A., M.D. |
Industry | Finance |
Cerevel Therapeutics Holdings Inc
$28.80
+0.66%
Vaxcyte Inc
$28.80
+0.66%
Janux Therapeutics Inc
$28.80
+0.66%
Spdr Nuveen S&p High Yield Municipal Bond Etf
$28.80
+0.66%
Radnet Inc
$28.80
+0.66%
The St. Joe Co
$28.80
+0.66%
Harley-davidson, Inc.
$28.80
+0.66%
Vaneck Vectors Fallen Angel Hiyld Bd Etf
$28.80
+0.66%
Aurora Innovation Inc
$28.80
+0.66%